Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 18, 2017

ICU MEDICAL, INC.

(Exact name of registrant as specified in its charter)
DELAWARE
 
001-34634
 
33-0022692
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)

951 Calle Amanecer, San Clemente, California
 
92673
(Address of principal executive offices)
 
(Zip Code)

(949) 366-2183

Registrant's telephone number, including area code
N/A

(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company o
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o








Item 8.01. Other Events

In connection with the Hospira Infusion Systems business that ICU Medical, Inc. (the “Company”) acquired in February 2017 from Pfizer, Inc., on April 18, 2017, the Company received a grand jury subpoena issued by the United States District Court for the Eastern District of Pennsylvania, in connection with an investigation by the U.S. Department of Justice, Antitrust Division. The subpoena calls for production of documents regarding the manufacturing, selling, pricing and shortages of intravenous ("IV") solutions, including saline, sold by the Company and communications with competitors regarding the same. In addition, the New York Attorney General has previously requested that the Company provide information regarding business practices in the IV solutions industry. Both of these investigations relate primarily to time periods prior to the Company’s ownership of the IV solutions business. The Company will fully cooperate with the U.S. Department of Justice and the New York Attorney General on these investigations.





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
ICU MEDICAL, INC.
 
 
 
 
Date: April 18, 2017
 
 
 
By:
 
/s/ Scott E. Lamb
 
 
 
 
 
 
Scott E. Lamb
 
 
 
 
 
 
Chief Financial Officer and Treasurer